Les facteurs hypothalamiques: acquisitions diagnostiques et therapeutiques recentes. [Hypothalamic factors: recent diagnostic and therapeutic advances]

Détails

ID Serval
serval:BIB_24B94175D441
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Les facteurs hypothalamiques: acquisitions diagnostiques et therapeutiques recentes. [Hypothalamic factors: recent diagnostic and therapeutic advances]
Périodique
Schweizerische Medizinische Wochenschrift
Auteur(s)
Gaillard  R. C.
ISSN
0036-7672 (Print)
Statut éditorial
Publié
Date de publication
08/1987
Volume
117
Numéro
34
Pages
1270-7
Notes
Comparative Study
English Abstract
Journal Article
Review --- Old month value: Aug 22
Résumé
During the last few years, many neuropeptides have been isolated, characterized and synthesized. Neuroendocrinology is one area in which there has been major progress, particularly through the isolation of two new hypothalamic factors, corticotropin releasing factor (CRF) and growth hormone releasing factor (GRF). CRF specifically stimulates pituitary secretion of ACTH and other peptides derived from pro-opiomelanocortin (beta-lipotropin, beta-endorphin), while GRF, together with somatostatin, controls secretion of the growth hormone. Knowledge of the structures of the hypothalamic factors has allowed the synthesis of the native substances as well as many potent analogues with agonist and antagonist properties. These substances have numerous clinical applications. LHRH or its analogues are presently used or being tested in various conditions such as treatment of hormone-related cancers (prostate, breast), endometriosis, idiopathic precocious puberty as well as in sterility problems. The recent availability of long acting somatostatin analogues has raised great therapeutic expectations in various endocrine and digestive diseases. Whereas GRF can be used in the treatment of short stature, CRF has so far not been shown to be a potential important therapeutic agent. However, its clinical application as a diagnostic test is clearly useful in many situations. There is a promising future for the clinical applications of these substances in various endocrine, digestive and perhaps in psychiatric diseases, and in hormone-related cancers.
Mots-clé
Aged Corticotropin-Releasing Hormone/diagnostic use Cushing Syndrome/diagnosis Female Gonadotropin-Releasing Hormone/therapeutic use Growth Disorders/drug therapy Growth Hormone-Releasing Hormone/diagnostic use/therapeutic use Humans Male *Pituitary Hormone-Releasing Hormones/diagnostic use/therapeutic use Prostatic Neoplasms/drug therapy Somatostatin/therapeutic use Thyrotropin-Releasing Hormone/diagnostic use
Pubmed
Web of science
Création de la notice
15/02/2008 17:57
Dernière modification de la notice
20/08/2019 14:03
Données d'usage